Committee recommends removing GLP‑1 weight‑loss coverage after three‑year review

Benefits consultant told the committee county spending on GLP‑1 medications for weight‑loss has grown to roughly $2.5 million annually and the number of members on those drugs rose by about 100 last year; she recommended removing coverage for weight‑loss uses while preserving coverage for medically necessary uses such as diabetes.